Lipid Oligonucleotides

Lipid Oligonucleotides(Lipid -siRNA,Lipid-Aptamer,Lipid -ASO)

Lipids have good biocompatibility and drug delivery capabilities, and are widely used for in vivo drug delivery. Oligonucleotide molecules have advantages in disease treatment, target recognition, etc. By coupling liposomes with nucleic acids, they can exert higher value. ALN-APP is an investigational RNAi therapeutic drug Amyloid-β precursor protein (APP). The previous clinical phase project used Alnylam's proprietary C16 siRNA conjugation platform for central nervous system (CNS) delivery to treat Alzheimer's disease (AD) and cerebral amyloid angiopathy (CAA). C16 is lipophilic and can interact with cell membranes or membrane proteins. The 2 '- O-C16 conjugated lipophilic small interfering RNA (siRNA) conjugate can target extrahepatic tissues, including the central nervous system, eyes, and lung tissues. The development of new delivery systems is beneficial for the further development of the pharmaceutical industry.

Schematic diagram of C16 coupled siRNA drug delivery principle

Biosyntech can provide various types of lipid coupled modified oligonucleotides, such as C16, C18, C20, C22, C24 modified oligonucleotides, and can also customize various lipid oligonucleotides according to customer needs. The following are commonly used 2 '- O-C16 modification structures: